In addition, exploration of MERTK expression levels in tumours using immunohistochemistry on tissue microarrays (TMAs) showed that high MERTK expression is a biomarker for worse overall, disease‐free and recurrence‐free survival in CRC patients. This evidence concerns the gene MERTK and colorectal carcinoma.